A clinical study on the prevention of relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia by donor NK cell infusion

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900028174

Enrollment

Unknown

Registered

2019-12-14

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Interventions

experimental group:Donor NK cell infusion

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The patients were diagnosed as acute myeloid leukemia and received allogeneic hematopoietic stem cell transplantation 2-3 months later. 2. Aged 18-65 years. 3. Physical strength score 0-3 (ECoG standard); 4. No obvious active infection and graft-versus-host disease; 5. The leukocyte count in the first month after transplantation was higher than 1.5 x 10^9 / L; 6. Serum creatinine = 50%, no pericardial effusion confirmed by echocardiography, no clinically significant abnormality found by ECG.

Exclusion criteria

Exclusion criteria: 1. The recurrence of primary disease after transplantation; 2. Central system leukemia; 3. Serious infection; 4. Acute graft-versus-host disease; 5. The subjects judged by the researchers are difficult to complete all the visits or operations required by the study plan (including the follow-up visits), or the compliance of participating in the study is insufficient.

Design outcomes

Primary

Measure	Time frame
Safety;	—

Secondary

Measure	Time frame
Effecacy;	—

Countries

China

Contacts

Public ContactHai Yi

The General Hospital of Western Theater Command

yihaimail@163.com+86 13699418229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026